Columns | View from Brussels

Slovenia brings EU health officials together for increased emphasis on repurposing.

Promises of "more equitable access for those with severe diseases," "decision-making flexibility where it counts," and more in a bid to win post-Brexit business.

European Commission proposes new bio-defense preparedness plan.

A draft report from parliament's cancer committee highlights the benefits that precision and personalized medicine offer.

Not just COVID is changing the landscape of pharmaceutical policy in Europe.

Allegedly more than 4,000 clinical trials of medicines are missing results on the European trial registry, in violation of transparency rules.

A new report from the EMA and EUnetHTA shows a shift towards a more efficient form of collaboration.

Conclusions from the Global Health Summit provide plenty of support for research, innovation, investment, and incentivization.

A major international collaboration within ICH features big hitters from across the world's major regulatory authorities and drug firms

Pressure mounts in Brussels as calls for new ways to debate pharma policies come from all directions.

Parliament's health committee is answering calls for a firmer grip on policies affecting the well-being of its 450 million citizens.

European Group on Ethics in Science and New Technologies issues cautious opinion on the use of gene editing amidst COVID vaccination controversy.

Rate of adoption in Europe for advanced diagnostics is falling behind that of others' globally.

A new partnership, to be known as EP PerMed, aims to bring public and private sector interests together.

Upcoming study reveals challenges faced by Europe over the pricing of pharmaceuticals.

The latest initiative against COVID, the European Health Emergency Preparedness and Response Authority, is taking shape with intentions of revealing the vulnerabilities in global supply chains and more.

After three years, member states of the EU have yet to make any real progress on legislation that would coordinate their clinical assessments more closely.

Cancer still a primary focus of EMA in light of COVID and vaccine development.

The $4 billion program will embrace the disease's entire pathway, from prevention to quality of life of patients and survivors.

After issuing a conditional marketing authorization issued just a week ago for the Moderna vaccine and receiving applications for more, the EU has reserved vaccines sufficient to treat more than 80% of the European population.

As the EMA gives Moderna's COVID vaccine the thumbs up, the European Commission has quickly followed up with its own approval.

Despite all the hopes and wishes for a better new year, the start to 2021 in Europe is proving to be grimly similar to the end of 2020.

The EU has its first COVID vaccine authorized.

Europe's leaders find themselves in a strange situation as their defense of their systematic approach to drug registration via the EMA has come under fire not only externally, but from some of their own politicians as well.

As the UK's Medicines and Healthcare products Regulatory Agency gave approval to the Pfizer/BioNTech COVID vaccine—questions about how they had been so quick, or why the EU had been so slow, have risen.

European health ministers are meeting later this week to review what has been, and what can be, done to strengthen future defenses to counter the COVID pandemic.

While the UK's departure from the EU is imminent, NICE will continue to influence thinking around the continent.

Dilemmas are multiple and stakes are high as the framework for thinking about medicines development frequently fluctuates because of the COVID-19 pandemic, making it harder to foresee all implications for the future.

As the EU moves towards the next stage in its review of intellectual property incentives for pharmaceuticals, some unusually direct exchanges occurred between those who advocate patents—and those who oppose them.